| Literature DB >> 31064325 |
Kshema Thakur1,2, Tarnjeet Kaur3, Manpreet Kaur3, Rachna Hora1, Jatinder Singh4.
Abstract
BACKGROUND: Lectins have come a long way from being identified as proteins that agglutinate cells to promising therapeutic agents in modern medicine. Through their specific binding property, they have proven to be anti-cancer, anti-insect, anti-viral agents without affecting the non-target cells. The Arisaema tortuosum lectin (ATL) is a known anti-insect and anti-cancer candidate, also has interesting physical properties. In the present work, its carbohydrate binding behavior is investigated in detail, along with its anti-proliferative property.Entities:
Keywords: Apoptosis; Complex N-glycans; Glycan array; ITC; Lectin; Molecular cloning
Mesh:
Substances:
Year: 2019 PMID: 31064325 PMCID: PMC6505227 DOI: 10.1186/s12867-019-0132-0
Source DB: PubMed Journal: BMC Mol Biol ISSN: 1471-2199 Impact factor: 2.946
Fig. 1Enthalpogram of Afet interaction with ATL. Upper panel shows raw ITC data obtained after each automatic injection (18 injections). Lower panel displays integrated curve comprising experimental data points (filled squares) and best fit (curved line) with one site model
Fig. 2Glycan array analysis of biotinylated ATL. Graph presented here is for 10 µg ml−1 lectin concentration. Binding intensity of lectin to glycans was expressed as RFU. Error bars represent mean ± standard deviation. Structures of strongest binding glycans according to ranking analysis and their respective numbers in the array are given. The symbols used for constructing structures are from Essentials of Glycobiology, 3rd edition, Appendix 1B: “Essentials Symbol Nomenclature” for Graphical Representations of Glycans (PMID 26543186)
Binding specificity of ATL towards various glycans as determined by microarray
| Glycan no. | Glycan structure | Avg. ranka |
|---|---|---|
| High mannose | ||
| 51 | Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 | 87.6 |
| 217 | Mana1-6(Mana1-3)Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 67.9 |
| 50 | Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 67.1 |
| 485 | Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp19 | 62.5 |
| 216 | Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 37.3 |
| 212 | Mana1-2Mana1-6(Mana1-3)Mana1-6(Mana1-2Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 35.7 |
| 211 | Mana1-6(Mana1-2Mana1-3)Mana1-6(Mana1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 30.4 |
| Complex | ||
| 389 | GlcNAcb1-2Mana1-6(GlcNAcb1-4(GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 | 85.5 |
| 404 | Gala1-4Galb1-3GlcNAcb1-2Mana1-6(Gala1-4Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 | 70.8 |
| 365 | Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 59.9 |
| 325 | Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp19 | 57.7 |
| 388 | Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 | 51.9 |
| 53 | GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp13 | 48.0 |
| 446 | Fuca1-2Galb1-4 GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4GlcNAcb1-2(Fuca1-2Galb1-4GlcNAcb1-4)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 25.9 |
| 370 | Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 | 24.5 |
| 352 | Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 15.5 |
| 52 | GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | 14.9 |
| 399 | Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 | 13.8 |
| 405 | Gala1-4Galb1-4GlcNAcb1-2Mana1-6(Gala1-4Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 | 11.8 |
| Fucosylated core | ||
| 355 | Galb1-3GlcNAcb1-2Mana1-6(Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp22 | 24.1 |
| 576 | Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 | 20.9 |
| 575 | GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 | 20.6 |
| 473 | Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 | 20.0 |
aAverage rank is based on analysis of RFU for three concentrations of lectin as discussed in text
Glycopattern findings for ATL
| Experiment (v5.0) | Motifs | Binders | Non binders |
|---|---|---|---|
| ATL | 3 | 25 | 586 |
| ATL (10.0 µg ml−1)a | 3 | 28 | 583 |
| ATL (1.0 µg ml−1)a | 3 | 14 | 597 |
| ATL (0.1 µg ml−1)a | 3 | 15 | 596 |
aIndicates the ATL concentration in specific experiment
Fig. 3Multiple sequence alignment showing conserved and lost CRS. Yellow boxed regions show conserved CRS while blue boxed regions show lost CRS in Araceae members in comparison to other mannose binding lectins
Fig. 4Sequence alignment of ATL with mannose binding (GNA, Tulipa) and non-mannose binding (Araceae) lectins from GNA-related lectin superfamily. Conserved CRS are highlighted in yellow boxes. Blue boxes highlight the CRS mutated in non-mannose binding Araceae lectins. Substitution of a conserved residue downstream of conserved CRS is highlighted in red box as against conserved residue in green. Accession numbers of lectins and their full forms are provided in Additional file 4: Table S3
Fig. 5Evolutionary relationship of ATL (highlighted with filled diamond label) with other phytolectins having CRS as inferred using the Neighbor-Joining method. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. All positions containing gaps and missing data were eliminated
Fig. 6Effect on IMR-32 cells of ATL treatment on: a the cell number as studied on time dependent lectin treatment in trypan blue dye exclusion assay. Values above the bars are t-values of comparison of cell number between control and treatment. Error bars indicate standard error. Significance levels are provided in the text. b Nucleic acid content of the cells. Best results out of the three experiments performed are presented. c Agarose gel pictures showing DNA damage. Labels above the lanes represent respective control and treatment stages
Fig. 7Morphology of IMR-32 cells as observed under phase contrast microscope under a control, b ATL treatment. Respective time stages of observation are provided at top of the photographs. Arrows indicate apoptotic bodies